News
Investor conference call today at
Recent Developments
-
PulseTx System enters the clinic as company works towards 510(k)
submission to
FDA before year end. PulseTx is a first of its kind NPS platform comprised of a tunable nanosecond pulse generator accompanied by a suite of interchangeable tissue applicators to enable treatments across a wide variety of applications. - First dermatologic human pilot study with the company’s proprietary PulseTx platform. Successful first clinical procedure with the PulseTx System in the company’s initial pilot study evaluating a range of NPS doses in abdominal skin. The objective of this first study is to establish the response and recovery time of skin to different NPS doses, enabling the company to better design further clinical studies in dermatology.
-
Results from three preclinical studies presented at the
Society for Immunotherapy of Cancer (SITC ) 2016 annual meeting. Presented preclinical findings which demonstrate NPS’ potential to effectively trigger immunogenic cell death, stimulate anti-tumor immunity responses, and inhibit metastases in a variety of oncologic conditions. -
Progress towards entering the clinic with an initial NPS pilot study in immuno-oncology.Pulse Biosciences is pursuing multiple paths for its first pilot study in oncology and expects to have the pilot study trial design and strategy defined by year-end.
“We are very pleased with our progress this quarter,” said
Financial Highlights
Cash, cash equivalents, and investments totaled
Operating expenses for third quarter ended
Conference Call Details
Pulse Biosciences’
About Pulse Biosciences
Pulse Biosciences is a medical technology company developing a therapeutic tissue treatment platform based on Nano-Pulse Stimulation, a proprietary bioelectronics cell signaling technology. Published pre-clinical studies have shown that a single, brief exposure of Nano-Pulse Stimulation to target tissue stimulates a cascade of events within cells and in the surrounding microenvironment that results in apoptosis (cell death) and the priming of a durable adaptive immune response. Pulse Biosciences is pursuing a variety of applications for its technology that exploits the technology’s unique biologic effect in immuno-oncology, dermatology, aesthetics, and veterinary medicine. Clinical studies are being planned using the first commercial system designed to support a broad array of applicators for use in superficial, minimally-invasive and open surgical procedures. More information is available at www.pulsebiosciences.com.
Forward Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things, the
development of Pulse Biosciences’ business, statements relating to
future uses and markets for its NPES technology, and other future
events. You should not place undue reliance on forward-looking
statements because they involve known and unknown risks, uncertainties,
changes in circumstances and other factors that are, in some cases,
beyond Pulse Biosciences’ control and could cause actual results to
differ materially from the information expressed or implied by
forward-looking statements made in this press release. Factors that
could materially affect actual results can be found in Pulse
Biosciences’ most recent filings with the
| PULSE BIOSCIENCES, INC. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (Unaudited) | ||||||||
| September 30, | December 31, | |||||||
|
(in thousands) |
2016 | 2015 | ||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 4,628 | $ | 3,606 | ||||
| Investments | 14,085 | — | ||||||
| Prepaid expenses and other current assets | 294 | 44 | ||||||
| Deferred offering costs | — | 347 | ||||||
| Total current assets | 19,007 | 3,997 | ||||||
| Equipment, net of accumulated depreciation | 323 | 329 | ||||||
| Intangible assets, net of accumulated amortization | 6,709 | 7,208 | ||||||
| Goodwill | 2,791 | 2,791 | ||||||
| Total assets | $ | 28,830 | $ | 14,325 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 446 | $ | 262 | ||||
| Accrued expenses | 521 | 398 | ||||||
| Total current liabilities | 967 | 660 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock | 13 | 8 | ||||||
| Additional paid-in capital | 37,655 | 16,745 | ||||||
| Accumulated comprehensive loss | (8 | ) | — | |||||
| Accumulated deficit | (9,797 | ) | (3,088 | ) | ||||
| Total stockholders’ equity | 27,863 | 13,665 | ||||||
| Total liabilities and stockholders’ equity | $ | 28,830 | $ | 14,325 | ||||
| PULSE BIOSCIENCES, INC. | ||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||
| (Unaudited) | ||||||||||||
|
|
Three-Month Periods Ended | |||||||||||
|
(in thousands, except per share amounts) |
September |
June 30, |
September |
|||||||||
| Revenue | $ | — | $ | — | $ | — | ||||||
| Operating expenses: | ||||||||||||
| General and administrative | 893 | 642 | 408 | |||||||||
| Research and development | 1,739 | 1,453 | 659 | |||||||||
| Amortization of intangible assets | 166 | 166 | 167 | |||||||||
| Total operating expenses | 2,798 | 2,261 | 1,234 | |||||||||
| Other income: | ||||||||||||
| Interest income | 31 | 3 | — | |||||||||
| Total other income | 31 | 3 | — | |||||||||
| Loss from operations, before income taxes | (2,767 | ) | (2,258 | ) | (1,234 | ) | ||||||
| Income tax benefit | — | — | 483 | |||||||||
| Net loss | $ | (2,767 | ) | $ | (2,258 | ) | $ | (751 | ) | |||
| Net loss per share | $ | (0.21 | ) | $ | (0.23 | ) | $ | (0.10 | ) | |||
| Weighted average number of shares | 13,315 | 9,791 | 7,565 | |||||||||
View source version on businesswire.com: http://www.businesswire.com/news/home/20161114006516/en/
Source:
Investors:
Pulse Biosciences, Inc.
Darrin Uecker, President
and Chief Executive Officer
IR@pulsebiosciences.com
or
Media:
Sam
Brown, Inc.
Hannah Hurdle, 818-456-4099
hannahhurdle@sambrown.com